He Bi Shi

Stroke is the second leading cause of death worldwide, with ischemic stroke being the most common type. The current best treatment for acute ischemic stroke is intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) given within 4.5 hours of symptom onset. However, some patients experience stroke progression or early blood vessel reocclusion after thrombolysis, which worsens neurological function and outcomes. This is believed to be caused by increased platelet activation after thrombolysis, which peaks within the first 2 hours. This clinical trial is testing whether starting oral aspirin early after intravenous thrombolysis can improve functional outcomes without causing more bleeding problems. Patients are randomly assigned to receive either 300 mg aspirin tablets or matching placebo tablets as soon as possible after enrollment. If swallowing is difficult, tablets can be crushed and given through a nasogastric tube. Both groups receive best medical management according to guidelines. The study is a Phase 3, multicenter, randomized, placebo-controlled trial. Participants will be followed for 90 days after stroke to measure their functional recovery using the modified Rankin scale (mRS). Researchers will check if patients have a good outcome defined as an mRS score of 0 or 1 at 90 days. During the study, patients undergo assessments including neurological exams and imaging to confirm eligibility and monitor safety. The trial aims to determine if early aspirin treatment after thrombolysis is safe and can help prevent neurological decline and improve recovery.

The study population are patients with acute anterior circulation large vessel occlusion stroke and planned to undergo endovascular treatment. All participants are randomly assigned in a 1:1 ratio to the tocilizumab group or the placebo group. In tocilizumab group, participants will receive tocilizumab combined endovascular treatment. And in placebo group, participants will receive placebo combined endovascular treatment. All participants will be visited immediately postoperatively, at 24 hours, 7 days, and 90 days after randomization.

This research aims to evaluate and compare treatments for people infected with Helicobacter pylori, a type of bacteria that can cause stomach problems. It is a Phase 4 multicenter prospective study including 200 patients confirmed positive for H. pylori by rapid urease test or 13C urea breath test. The study will follow ethical guidelines and obtain informed consent from all participants before enrollment. Researchers will assess factors such as antibiotic resistance, success rates, adverse reactions, and patient compliance during treatment. Participants will receive either a high-dose dual therapy or a quadruple therapy containing minocycline and other medications. The drugs studied include vonoprazan (a potassium competitive acid blocker), amoxicillin, bismuth potassium citrate (which protects the stomach lining and fights H. pylori), and a combination of minocycline and metronidazole antibiotics. All patients will undergo H. pylori culture and drug sensitivity testing to guide therapy. During the study, researchers will monitor the eradication rate of H. pylori six weeks after therapy completion. They will also observe adverse reactions and patient adherence to treatment. The study includes careful follow-up and assessments to measure treatment outcomes and antibiotic resistance impact. The total participation period and further follow-up details are guided by study protocols to ensure comprehensive evaluation of therapies.

Chronic obstructive pulmonary disease (COPD) is a common long-term lung condition often accompanied by other health issues. These overlapping conditions can cause symptoms to change, lead to sudden worsening of COPD, hospital stays, and ongoing disease progression. The IMPACT COPD Cohort (China) is a large, multi-center observational study designed to gather real-world data on managing COPD along with its related health problems using both Chinese and Western medical approaches. Participants will continue receiving usual medical care based on established GOLD guidelines and local practices. The study collects ongoing data through standard clinical tests including symptom questionnaires, lung function tests, imaging, and biomarker analysis. Additionally, participants will use continuous multisensor digital devices that monitor heart rate, blood pressure, physical activity, sleep patterns, and other physiological and behavioral signs. Digital Traditional Chinese Medicine assessments such as tongue, pulse, and facial diagnostics will also be performed. No specific treatments are assigned by the study. Throughout the study, researchers will gather and analyze data on participants’ health status, lung function, and comorbidity development over up to 36 months. They will monitor the yearly rate of COPD flare-ups and track related conditions like hypertension, heart disease, and diabetes. The study aims to identify risk factors, develop prediction tools for acute episodes and comorbidities, and support long-term management strategies including early detection and risk warnings across hospital, community, and home settings.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients who have experienced an acute ischemic stroke. This prospective, multicenter, randomized controlled Phase 4 trial focuses on patients aged 70 years and older who receive treatment within 4.5 hours of stroke onset. The study aims to compare low-dose tenecteplase with the standard dose to understand its impact on stroke recovery in aging patients. Participants are randomly assigned to one of two groups: a low-dose group receiving tenecteplase at 0.175 mg/kg (up to 17.5 mg per patient) or a standard-dose group receiving tenecteplase at 0.25 mg/kg (up to 25 mg per patient). Treatment is administered intravenously as thrombolysis. The trial monitors patients closely to assess how these dosing strategies affect recovery and safety. During the study, researchers will evaluate neurological function using the Modified Rankin Scale 90 days after treatment, measuring the percentage of participants who achieve a score of 0 or 1, indicating no symptoms or no significant disability. Patients will undergo neurological assessments and safety monitoring throughout the trial. The study ensures informed consent and collects relevant clinical data to support its findings on tenecteplase use in elderly stroke patients.

Researchers are conducting a multicenter, prospective, observational real-world study across 200 hospitals in China to examine treatment patterns for chronic hepatitis B (CHB). The study aims to compare patient outcomes under various therapies to provide evidence-based data that can help optimize CHB treatment and follow-up, with the ultimate goal of advancing a functional cure for chronic hepatitis B. The focus includes monitoring the incidence of hepatocellular carcinoma (HCC) associated with hepatitis B. Participants receive treatments including entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF), or Peginterferon α-2b injection. The study follows both patients currently on these therapies and those initiating or re-initiating Peginterferon α-2b therapy. These treatments are assessed in routine clinical practice settings without intervention from the study team. Throughout the study, patients are monitored from week 4 up to week 240 for the development of HBsAg-associated hepatocellular carcinoma (HCC) and overall HCC incidence. Researchers collect data on treatment effectiveness and safety as part of the observational follow-up. Participants provide informed consent and are observed under real-world conditions to evaluate long-term outcomes and risks associated with chronic hepatitis B and its treatments.

Researchers are investigating the safety and effectiveness of remote ischemic conditioning (RIC) in patients with acute ischemic stroke caused by large vessel blockage in the brain. While endovascular thrombectomy is effective in reopening blocked vessels, many patients still suffer poor outcomes due to brain tissue damage during and after the procedure. The study aims to see if RIC, a noninvasive therapy involving brief cycles of arm blood flow restriction, can protect the brain and improve recovery in these patients. The study compares two durations of remote ischemic conditioning: one lasting 14 days and another lasting 30 days after mechanical thrombectomy. RIC is performed using an automatic device that inflates and deflates a cuff on the upper arm, with five cycles of 5-minute inflation and 5-minute deflation. This procedure is done once before thrombectomy and then twice daily during the assigned post-thrombectomy period. All patients also receive best medical management according to guidelines. Mechanical thrombectomy is done following standard practices to reopen blocked vessels safely. Participants will be monitored for 90 days after their stroke to assess recovery and safety. The main measure is the proportion of patients who achieve a good functional outcome, defined as a modified Rankin Scale score of 0 to 2 at 90 days. Throughout the study, medical evaluations, imaging, and clinical assessments will be conducted to track progress and any side effects. The study also explores how the length of RIC treatment affects patient outcomes, aiming to find the best approach to protect the brain after stroke treatment.